JP2003535890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535890A5 JP2003535890A5 JP2002503266A JP2002503266A JP2003535890A5 JP 2003535890 A5 JP2003535890 A5 JP 2003535890A5 JP 2002503266 A JP2002503266 A JP 2002503266A JP 2002503266 A JP2002503266 A JP 2002503266A JP 2003535890 A5 JP2003535890 A5 JP 2003535890A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- methyl
- pyrrol
- carbonyl
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 33
- -1 epipodophyllotoxin compound Chemical class 0.000 description 29
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 16
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 102000003915 DNA Topoisomerases Human genes 0.000 description 6
- 108090000323 DNA Topoisomerases Proteins 0.000 description 6
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 6
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 6
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 6
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 6
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 6
- 229960005420 etoposide Drugs 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 150000001875 compounds Chemical group 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 2
- 0 CC(*)NC(C(C)=C)=O Chemical compound CC(*)NC(C(C)=C)=O 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 150000001251 acridines Chemical class 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229950010159 nemorubicin Drugs 0.000 description 2
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 108010042747 stallimycin Proteins 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- KOOUJYPZUNDPFO-UHFFFAOYSA-N n-(3-amino-3-iminopropyl)-4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C(Br)=C)C=2)C)=CN1C KOOUJYPZUNDPFO-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015444.3A GB0015444D0 (en) | 2000-06-23 | 2000-06-23 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors |
| GB0015444.3 | 2000-06-23 | ||
| PCT/EP2001/007059 WO2001097789A2 (en) | 2000-06-23 | 2001-06-20 | Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003535890A JP2003535890A (ja) | 2003-12-02 |
| JP2003535890A5 true JP2003535890A5 (enExample) | 2008-08-07 |
Family
ID=9894285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503266A Abandoned JP2003535890A (ja) | 2000-06-23 | 2001-06-20 | アクリロイルジスタマイシン誘導体並びにトポイソメラーゼｉ及びｉｉ阻害剤を含む薬剤組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20030162722A1 (enExample) |
| EP (1) | EP1292290B1 (enExample) |
| JP (1) | JP2003535890A (enExample) |
| KR (1) | KR100853955B1 (enExample) |
| CN (1) | CN1241573C (enExample) |
| AT (1) | ATE323483T1 (enExample) |
| AU (2) | AU7846301A (enExample) |
| BR (1) | BR0111813A (enExample) |
| CA (1) | CA2411172C (enExample) |
| CZ (1) | CZ20024155A3 (enExample) |
| DE (1) | DE60118914T2 (enExample) |
| DK (1) | DK1292290T3 (enExample) |
| EA (1) | EA006684B1 (enExample) |
| EE (1) | EE05319B1 (enExample) |
| ES (1) | ES2261448T3 (enExample) |
| GB (1) | GB0015444D0 (enExample) |
| HK (1) | HK1054334B (enExample) |
| HU (1) | HUP0301257A2 (enExample) |
| IL (1) | IL153177A0 (enExample) |
| MX (1) | MXPA02012163A (enExample) |
| NO (1) | NO329783B1 (enExample) |
| NZ (1) | NZ523000A (enExample) |
| PL (1) | PL200503B1 (enExample) |
| PT (1) | PT1292290E (enExample) |
| SK (1) | SK287549B6 (enExample) |
| WO (1) | WO2001097789A2 (enExample) |
| ZA (1) | ZA200209834B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0015444D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors |
| GB0015447D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents |
| PT1461083E (pt) * | 2002-01-02 | 2006-08-31 | Nerviano Medical Sciences Srl | Terapia combinada contra tumores que compreende derivados de distamicina de acriloilo substituidos e de inibidores de proteina-quinase (serina/treonina-quinase) |
| CN100438913C (zh) * | 2004-11-22 | 2008-12-03 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
| MD24Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare |
| MD36Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare |
| MD35Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare |
| MD23Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare |
| MX2013000250A (es) | 2010-07-02 | 2013-10-28 | Angiochem Inc | Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos. |
| CN109718228A (zh) * | 2017-10-30 | 2019-05-07 | 沈阳药科大学 | 米托蒽醌的抗肿瘤淋巴转移作用及其药物制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9615692D0 (en) * | 1996-07-25 | 1996-09-04 | Pharmacia Spa | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
| GB9623522D0 (en) | 1996-11-11 | 1997-01-08 | Pharmacia & Upjohn Spa | Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents |
| GB9727524D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| GB9806692D0 (en) * | 1998-03-27 | 1998-05-27 | Pharmacia & Upjohn Spa | Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents |
| GB0015444D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors |
-
2000
- 2000-06-23 GB GBGB0015444.3A patent/GB0015444D0/en not_active Ceased
-
2001
- 2001-06-20 MX MXPA02012163A patent/MXPA02012163A/es active IP Right Grant
- 2001-06-20 WO PCT/EP2001/007059 patent/WO2001097789A2/en not_active Ceased
- 2001-06-20 DE DE60118914T patent/DE60118914T2/de not_active Expired - Lifetime
- 2001-06-20 KR KR1020027017440A patent/KR100853955B1/ko not_active Expired - Fee Related
- 2001-06-20 CA CA002411172A patent/CA2411172C/en not_active Expired - Fee Related
- 2001-06-20 PL PL360297A patent/PL200503B1/pl not_active IP Right Cessation
- 2001-06-20 AT AT01956495T patent/ATE323483T1/de not_active IP Right Cessation
- 2001-06-20 DK DK01956495T patent/DK1292290T3/da active
- 2001-06-20 CN CNB018116396A patent/CN1241573C/zh not_active Expired - Fee Related
- 2001-06-20 IL IL15317701A patent/IL153177A0/xx not_active IP Right Cessation
- 2001-06-20 BR BR0111813-7A patent/BR0111813A/pt not_active Application Discontinuation
- 2001-06-20 AU AU7846301A patent/AU7846301A/xx active Pending
- 2001-06-20 CZ CZ20024155A patent/CZ20024155A3/cs unknown
- 2001-06-20 HU HU0301257A patent/HUP0301257A2/hu unknown
- 2001-06-20 ES ES01956495T patent/ES2261448T3/es not_active Expired - Lifetime
- 2001-06-20 JP JP2002503266A patent/JP2003535890A/ja not_active Abandoned
- 2001-06-20 EE EEP200200681A patent/EE05319B1/xx not_active IP Right Cessation
- 2001-06-20 EP EP01956495A patent/EP1292290B1/en not_active Expired - Lifetime
- 2001-06-20 AU AU2001278463A patent/AU2001278463B2/en not_active Ceased
- 2001-06-20 HK HK03106770.0A patent/HK1054334B/zh not_active IP Right Cessation
- 2001-06-20 SK SK1833-2002A patent/SK287549B6/sk not_active IP Right Cessation
- 2001-06-20 PT PT01956495T patent/PT1292290E/pt unknown
- 2001-06-20 NZ NZ523000A patent/NZ523000A/en unknown
- 2001-06-20 EA EA200300060A patent/EA006684B1/ru not_active IP Right Cessation
- 2001-06-20 US US10/297,915 patent/US20030162722A1/en not_active Abandoned
-
2002
- 2002-12-04 ZA ZA200209834A patent/ZA200209834B/en unknown
- 2002-12-18 NO NO20026078A patent/NO329783B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU773506B2 (en) | Antitumour synergistic composition | |
| JP2003535890A5 (enExample) | ||
| CA2411172C (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors | |
| AU2002221622B2 (en) | Antitumor therapy comprising distamycin derivatives | |
| AU2001278463A1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors | |
| AU2002221622A1 (en) | Antitumor therapy comprising distamycin derivatives | |
| CA2410160C (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents | |
| CA2409664A1 (en) | Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione | |
| EP1889624B1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | |
| JP2003535891A5 (enExample) | ||
| AU2001281867A1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents | |
| JP2003535874A5 (enExample) | ||
| JP2007500158A5 (enExample) | ||
| CA2472008C (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors | |
| US20070249651A1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors | |
| AU2001267553A1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | |
| JP2007537244A5 (enExample) |